Introduction
============

Lung cancer is a disease with one of the highest morbidity and mortality rates worldwide, and long-term survival remains poor. The majority of lung cancers are diagnosed at an advanced stage, when the opportunity for surgery has been missed. Radiotherapy is one of the most important therapeutic strategies in these patients, but its efficacy is not satisfactory, not only because of the emergence of resistance, but also because of reduced immune function during treatment.

Nonmethylated cytosine-phosphate-guanine (CpG) dinucleotides, present in bacterial DNA and recognized via Toll-like receptor 9 on plasmacytoid dendritic cells and B cells, are known to induce both innate and adaptive immunity,[@b1-ott-6-549] with the production of cytokines, such as tumor necrosis factor- alpha (TNF-α), interleukin (IL)-12, and interferon gamma, needed for development of antitumor immunity.[@b2-ott-6-549]--[@b4-ott-6-549] Recent studies show that CpG oligodeoxyribonucleotides (ODNs) can directly induce apoptosis in cancer cells, alter the cell cycle, and increase the sensitivity of chemotherapy and radiotherapy. [@b5-ott-6-549]--[@b9-ott-6-549] However, whether it has a dose-effect relationship when combined with radiotherapy has not been well investigated. On the basis of current studies, we used different doses of CpG ODN 1826 combined with fractionated irradiation (IR) to treat mice with Lewis lung cancer cell implants in order to investigate dose-relevant interactions between CpG ODNs and radiotherapy.

Materials and methods
=====================

Main instruments and reagents
-----------------------------

The Lewis lung cancer cells used in this study were kindly supplied by the Life Science Institute of Academy in Shanghai and cultured in RPMI-1640 medium (Biowest Therapeutics Inc, Vancouver, Canada) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The cultures were maintained at 37.8°C in a humidified atmosphere containing 5% CO~2~. The phosphorothioate-modified CpG ODNs were provided by Shanghai Sangon Biological Engineering Technology and Service Limited Company (Shanghai, People's Republic of China). The sequence of CpG ODN 1826 was 5′-TCCATGACGTTCCTGACGTT-3′. ODNs were diluted with phosphate-buffered saline to a concentration of 1 g/L and maintained at −20°C. Serum levels of TNF-α and IL-12 were measured using a standard Quantikine enzyme-linked immunosorbent assay kit from R&D Systems (Minneapolis, MN). A TdT-mediated dUTP nick end labeling (TUNEL) kit purchased from Beijing Tianyin Biochemical Technology Limited Company (Beijing, People's Republic of China) was used to detect tumor cell apoptosis. A linear accelerator was used (Precise 5839, Elekta, Stockholm, Sweden).

Tumor-bearing mouse model
-------------------------

Female C57BL/6 J mice were provided by the Shanghai Experimental Animal Center and maintained in a specific pathogen-free grade animal room until 6--8 weeks of age and weighing 18--22 g. They were housed at 6--7 per cage. The study was approved by the ethics committee of Jinshan Hospital, Shanghai, People's Republic of China. Approximately 4 × 10^6^ Lewis lung cancer cells were injected subcutaneously into the right anterior leg of each mouse when the cells were in the exponential growth phase. A tumor bulb could be seen on the right anterior leg seven days after the tumor cells were injected. In total, there were 64 tumor-bearing mice in this experiment.

Experimental methods
--------------------

The experiment was started when the tumors were 6--8 mm in diameter. The mice were evenly randomized into eight groups. There was no treatment in the control group. Injections of CpG ODN 1826 were given intraperitoneally as a single dose of 0.05 mg, 0.1 mg, or 0.15 mg three times daily, on days 1, 2, and 9; the total dose of CpG ODN 1826 administered was 0.15 mg, 0.3 mg, and 0.45 mg. On the second day of the experiment, the nonanesthetized mice were tied to small boards, and their tumors were centered in a 3 cm^2^ field. Radiation was delivered five times to the tumor-bearing leg using a linear x-ray accelerator unit with a single dose of 2.5 Gy on days 2--6, for a total dose of 12.5 Gy. In the mice receiving both radiation and CpG ODN 1826, radiation was given three hours after administration of CpG ODNs. On day 16, tumor-bearing mice (except for three surviving mice that became tumor-free) were euthanized for investigation.

Efficacy in transplanted tumors
-------------------------------

Starting on day 5 after inoculation, we weighed all tumor-bearing mice in the eight treatment groups on alternate days, and recorded their mental status, eating habits, behavioral characteristics, and any deaths. The effects of different doses of CpG ODN 1826 and IR were well demonstrated by a delay in tumor growth and the sensitization enhancement ratio. The absolute tumor growth delay (ATGD) is defined as the time (days) for tumors in the treatment groups (IR ± CpG ODN 1826) to grow from the original mean volume to four times that volume minus the time (days) taken for the tumors in the untreated control group to reach the same size.[@b10-ott-6-549] The sensitization enhancement ratio (SER) is defined as the value of ATGD in different dose of CpG ODN 1826 combined with IR groups divided by the ATGD in IR group. To obtain the tumor growth curve, we used a vernier caliper to measure the tumor diameters, and mean values were calculated. Tumor volume was calculated as:
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where *a* is the maximum diameter of the tumor and *b* is the maximum diameter perpendicular to *a*. The tumor inhibitory rate was calculated as:
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Cell apoptosis
--------------

A TUNEL kit was used to detect apoptosis in tumor cells, whereby apoptotic cell nuclei stain brown and nonapoptotic cells stain blue. Cell apoptosis was observed under a microscope by two pathologists working independently. The apoptosis rate was calculated as follows: (number of apoptosis cells/total number of cells) × 100%.[@b12-ott-6-549]

Impact on immune function
-------------------------

On day 16, the serum was collected and all spleen, thymus, and tumor tissue was removed from the mice. A standard Quantikine enzyme-linked immunosorbent assay kit from R&D Systems was used to measure serum TNF-α and IL-12 levels. Mean spleen and thymus exponents were calculated as the weight of the spleen divided by the weight of the mouse from which the tumor had been removed. We also observed growth of Lewis lung cancer cells reinoculated into the mice that had been cured.

Statistical analysis
--------------------

Statistical analysis was done using the Statistical Package for Social Sciences version 17.0 (SPSS Inc, Chicago, IL, USA). Data are expressed as the mean ± standard deviation. The Student's *t*-test was used to test for differences between the groups. Differences resulting in *P* \< 0.05 were considered to be statistically significant.

Results
=======

Mouse model
-----------

Sixty-four tumor-bearing mice were successfully created and treated with different doses of CpG ODN 1826, fractionated local tumor IR, or both CpG ODN 1826 and IR. Eight nontreated mice served as a control group, of which three died between days 13 and 15. The mental status, eating habits, and behavioral characteristics of the mice worsened in the control group. With the concentration of CpG ODNs increasing, the general survival condition was improved in the treated groups. One mouse in the CpG 0.3 + IR group and two surviving mice in the CpG 0.45 + IR group became tumor-free.

Tumor growth
------------

CpG ODN 1826 has potent antitumor effects in vivo.[@b13-ott-6-549] Our study was intended to determine if there is a synergistic effect between CpG ODN 1826 and IR in terms of tumor growth. As shown in [Figure 1](#f1-ott-6-549){ref-type="fig"}, from day 3 onwards, the mean tumor volumes in the treatment groups were smaller than that in the control group, with the lowest tumor volume recorded in the CpG 0.45 + IR group. On the last day, the mean tumor volume was 6.21 ± 0.45 cm^3^ in the control group, 4.82 ± 0.34 cm^3^ in the irradiation group, 5.14 ± 0.36 cm^3^ in the CpG ODN 0.15 group, 4.72 ± 0.35 cm^3^ in the CpG ODN 0.3 group, 4.32 ± 0.32 cm^3^ in the CpG ODN 0.45 group, 3.71 ± 0.43 cm^3^ in the CpG ODN 0.15 + IR group, 2.53 ± 0.29 cm^3^ in the CpG ODN 0.3 + IR group, and 1.58 ± 0.34 cm^3^ in the CpG ODN 0.45 + IR group. There was no statistically significant difference in tumor volume between the groups before treatment while the tumor volume was remarkably decreased after treatment (*P* \< 0.05). The therapeutic effect was most marked in the CpG ODN 0.45 + IR group (*P* \< 0.05). [Table 1](#t1-ott-6-549){ref-type="table"} shows that a total dose of 12.5 Gy given in 2.5 Gy fractions produced an ATGD of 2.0 days. CpG ODN 1826 alone delayed tumor growth for 1.8--2.3 days. In contrast, CpG ODN 1826 or IR was very effective, and the ATGD for these tumors was 4.4--6.0 days, with a sensitization enhancement ratio of 2.0, 2.7, and 3.0. This ATGD value was considerably higher than the sum of the tumor growth delay seen with each individual treatment, and this difference was statistically significant (*P* \< 0.05). Moreover, ATGD and sensitization enhancement ratios increased with increasing concentrations of CpG ODN 1826.

Cell apoptosis
--------------

Apoptosis in Lewis lung cancer tumor cells in the control group and the groups treated with different doses of CpG ODN 1826 ± IR was assessed by TUNEL. As shown in [Table 2](#t2-ott-6-549){ref-type="table"} and [Figure 2](#f2-ott-6-549){ref-type="fig"}, when mice were treated with different doses of CpG ODN 1826 or IR, the apoptosis rate was obviously higher than that in the nontreated mice (*P* \< 0.05). Moreover, when mice were treated with the two abovementioned therapies in combination, the apoptosis rate was significantly higher than when either treatment was administered alone (*P* \< 0.05). Further, efficacy increased with increasing doses of CpG ODN 1826.

Impact on immune function
-------------------------

As shown in [Table 3](#t3-ott-6-549){ref-type="table"}, TNF-α and IL-12 levels were significantly lower in the group treated with IR alone than in the control group (*P* \< 0.05), indicating that radiation might reduce immune function in mice. However, these indices were higher in the CpG ODN 1826 group than in the control group (*P* \< 0.05), and there was no significant difference between the group receiving the low dose of CpG ODN 1826 and the control group. Meanwhile, compared with the IR group, TNF-α and IL-12 levels increased gradually when the mice were treated with increasing doses of CpG ODN 1826 + IR (*P* \< 0.05). A similar pattern of change in the spleen and thymus exponents was seen. Another research question was whether CpG ODN 1826 affected the secondary immune response, so Lewis lung cancer cells were reinoculated in the three tumor-free surviving mice. After ten days of observation, no transplanted tumors grew in these mice.

Discussion
==========

Radiotherapy is the first-line treatment option for advanced cancer. However, immune function is severely compromised by radiotherapy, resulting in physical decline and limited therapeutic effect, and is a major limiting factor using this treatment modality. The innate immune system is geared towards providing a rapid response to foreign pathogens by pattern recognition receptors that distinguish prokaryotic from eukaryotic DNA.[@b14-ott-6-549] These receptors bind specifically to nonmethylated CpG dinucleotides, enabling bacteria and other pathogens to stimulate the innate immune system. Synthetic ODNs containing nonmethylated CpG motifs mimic bacterial DNA and can activate the immune response. They can also activate a multitude of immunocytes, generating a cascade of cytokines which trigger apoptosis and inhibit tumor growth.[@b15-ott-6-549] In light of these observations, we undertook this study to determine if CpG ODNs can reduce the immune suppression caused by radiation and thereby increase its therapeutic effect, and if so, whether there was a dose-response relationship for CpG ODNs.

The results of this study show that treatment using CpG ODN 1826 in mice bearing large established tumors markedly enhanced the tumoral response to fractionated IR. Enhancement of the treatment response was evident in the longer delay in tumor growth, an improved sensitization enhancement ratio, and a higher rate of apoptosis than that achieved by IR alone. CpG ODN 1826 or IR alone produced an ATGD of about 2.0 days while the different doses of CpG ODN 1826 + IR improved the ATGD to 4.4--6.0 days and the sensitization enhancement ratio to 2.0--3.0. In addition, the apoptosis rate in mice treated with CpG ODN 1826 or IR alone was significantly higher (*P* \< 0.05). Moreover, when mice received both treatments, the apoptosis rate was significantly higher than that in mice which received either treatment alone. Further, with increasing doses of CpG ODN 1826, the antitumor effect became more significant. These results show that CpG ODN 1826 can induce apoptosis, and further, that it augments the effect of IR, with some degree of dose-response relationship.

What's more, a more powerful immune function, which was demonstrated by detecting the concentration of TNF-α and IL-12 in serum and the spleen and thymus exponent, than that from IR alone was observed in groups combined with CpG ODN 1826 and IR. There was no significant difference in effect between the group receiving the low dose of CpG ODN 1826 and the control group. With increasing doses of CpG ODN 1826 in the combination therapy groups, the immuno-protective effect became increasingly significant. In contrast, CpG ODN 1826 alone or combined with IR could increase serum TNF-α and IL-12 levels and increased the spleen and thymus exponents, while IR alone decreased these parameters and immune activation, indicating a dose-dependent relationship. Moreover, in view of the failed reinoculation in tumor-free surviving mice, we hypothesize that CpG ODNs trigger production of cytokines like IL-12 and IL-18 in the body to activate memory lymphocytes, which is similar to the conclusion drawn by Kawarada et al.[@b16-ott-6-549] Our results show that CpG ODNs, a powerful inducer of antitumor immunity, can protect against radiotherapy-induced immune dysfunction and induce a memory immune response against tumor antigens.

Existing investigations have shown that CpG ODNs have not only the full range of stimulation to body's immune system but also the antitumor effects, which provided a spacious perspective for people in preventing and curing malignant tumors. However, these studies have only investigated the effects of CpG ODN 1826 in mice. Further research will be required to clarify the mechanism involved, the dose of CpG ODNs required, and the reason for more destructive effects in the human body than in mice.
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###### 

Delay in tumor growth (days) and sensitization enhancement ratio

  Group               Mice (n)   Time   ATGD   SER
  ------------------- ---------- ------ ------ -----
  Control             5          1.8    --     --
  IR                  8          3.8    2.0    --
  CpG ODN 0.15        8          3.6    1.8    --
  CpG ODN 0.3         8          3.8    2.0    --
  CpG ODN 0.45        8          4.5    2.3    --
  CpG ODN 0.15 + IR   8          6.2    4.4    2.2
  CpG ODN 0.3 + IR    7          7.2    5.4    2.7
  CpG ODN 0.45 + IR   6          7.8    6.0    3.0

**Note:** Time taken (days) for tumors in the treatment groups (X-ray or CpG ODN 1826) to grow from their mean original volume to four times that volume.

**Abbreviations:** ATGD, absolute tumor growth delay; CpG, cytosine-guanine; IR, irradiation; n, number; ODN, oligodeoxyribonucleotide; SER, sensitization enhancement ratio.

###### 

Apoptosis rate in tumor cells (mean ± standard deviation)

  Group               Mice (n) (start)   Mice (n) (end)   Apoptosis rate (%)
  ------------------- ------------------ ---------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Control             8                  5                2.40 ± 0.55
  IR                  8                  8                7.13 ± 0.83
  CpG ODN 0.15        8                  8                5.50 ± 0.76[a](#tfn4-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.3         8                  8                11.63 ± 1.06[b](#tfn5-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.45        8                  8                19.13 ± 0.83[c](#tfn6-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.15 + IR   8                  8                12.88 ± 0.83[a](#tfn4-ott-6-549){ref-type="table-fn"},[d](#tfn7-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.3 + IR    8                  7                20.57 ± 2.37[a](#tfn4-ott-6-549){ref-type="table-fn"},[d](#tfn7-ott-6-549){ref-type="table-fn"},[e](#tfn8-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.45 + IR   8                  6                28.17 ± 3.31[a](#tfn4-ott-6-549){ref-type="table-fn"},[d](#tfn7-ott-6-549){ref-type="table-fn"},[f](#tfn9-ott-6-549){ref-type="table-fn"}

**Notes:**

*P* \< 0.05 versus control at *t* = 7.91, 24.73, 16.61, and 17.05;

*P* \< 0.05 versus CpG ODN 0.15 at *t* = 13.30;

*P* \< 0.05 versus CpG ODN 0.3 at *t* = 15.72;

*P* \< 0.05 versus IR at *t* = 13.78, 15.08, and 17.47;

*P* \< 0.05 versus CpG ODN 0.15 + IR at *t* = 8.63;

*P* \< 0.05 versus CpG ODN 0.3 + IR at *t* = 4.81.

**Abbreviations:** CpG, cytosine-guanine; IR, irradiation; n, number; ODN, oligodeoxyribonucleotides.

###### 

Concentrations of TNF-α, and spleen and thymus exponent (mean ± standard deviation)

  Group               Mice (n) (start/end)   TNF-α (μg/L)                                                                                                                                     Spleen exponent (mg/g)                                                                                                                         Thymus exponent (mg/g)
  ------------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Control             8/5                    126.84 ± 12.11                                                                                                                                   8.88 ± 1.60                                                                                                                                    2.25 ± 0.61
  IR                  8/8                    131.11 ± 14.13                                                                                                                                   9.66 ± 2.17                                                                                                                                    2.31 ± 0.57
  CpG ODN 0.15        8/8                    138.97 ± 9.27                                                                                                                                    9.74 ± 1.46                                                                                                                                    2.58 ± 0.42
  CpG ODN 0.3         8/8                    149.59 ± 9.60[a](#tfn12-ott-6-549){ref-type="table-fn"},[b](#tfn13-ott-6-549){ref-type="table-fn"}                                               12.49 ± 1.56[a](#tfn12-ott-6-549){ref-type="table-fn"},[b](#tfn13-ott-6-549){ref-type="table-fn"}                                              3.11 ± 0.43[a](#tfn12-ott-6-549){ref-type="table-fn"},[b](#tfn13-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.45        8/8                    171.81 ± 8.06[a](#tfn12-ott-6-549){ref-type="table-fn"},[b](#tfn13-ott-6-549){ref-type="table-fn"},[c](#tfn14-ott-6-549){ref-type="table-fn"}    15.68 ± 2.69[a](#tfn12-ott-6-549){ref-type="table-fn"},[b](#tfn13-ott-6-549){ref-type="table-fn"},[c](#tfn14-ott-6-549){ref-type="table-fn"}   3.74 ± 0.41[a](#tfn12-ott-6-549){ref-type="table-fn"},[b](#tfn13-ott-6-549){ref-type="table-fn"},[c](#tfn14-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.15 + IR   8/8                    133.23 ± 13.81                                                                                                                                   9.89 ± 2.23                                                                                                                                    2.45 ± 0.39
  CpG ODN 0.3 + IR    8/8                    156.96 ± 9.48[d](#tfn15-ott-6-549){ref-type="table-fn"},[e](#tfn16-ott-6-549){ref-type="table-fn"}                                               13.71 ± 2.36[d](#tfn15-ott-6-549){ref-type="table-fn"},[e](#tfn16-ott-6-549){ref-type="table-fn"}                                              3.06 ± 0.62[d](#tfn15-ott-6-549){ref-type="table-fn"},[e](#tfn16-ott-6-549){ref-type="table-fn"}
  CpG ODN 0.45 + IR   8/8                    179.37 ± 11.50[d](#tfn15-ott-6-549){ref-type="table-fn"},[e](#tfn16-ott-6-549){ref-type="table-fn"},[f](#tfn17-ott-6-549){ref-type="table-fn"}   16.36 ± 2.26[d](#tfn15-ott-6-549){ref-type="table-fn"},[e](#tfn16-ott-6-549){ref-type="table-fn"},[f](#tfn17-ott-6-549){ref-type="table-fn"}   3.90 ± 0.68[d](#tfn15-ott-6-549){ref-type="table-fn"},[e](#tfn16-ott-6-549){ref-type="table-fn"},[f](#tfn17-ott-6-549){ref-type="table-fn"}

**Notes:**

*P* \< 0.05 versus control at *t* = 3.770, 8.104, 4.026, 5.062, 3.008, and 5.326;

*P* \< 0.05 versus CpG ODN 0.15 at *t* = 2.249, 7.557, 3.644, 5.482, 2.496, and 5.579;

*P* \< 0.05 versus CpG ODN 0.3 at *t* = 5.012, 2.899, and 2.984;

*P* \< 0.05 versus IR at *t* = 4.298, 7.495, 3.575, 6.052, 2.494, and 5.051;

*P* \< 0.05 versus CpG ODN 0.15 + IR at *t* = 4.008, 7.263, 3.325, 5.762, 2.344, and 5.222;

*P* \< 0.05 versus CpG ODN 0.3 + IR at *t* = 4.255, 2.303, and 2.572.

**Abbreviations:** CpG, cytosine-guanine; IR, irradiation; ODN, oligodeoxyribonucleotides; TNF-α, tumor necrosis factor-alpha.
